> LaMattina counters that pricing should be based not on R&D costs but on the value a drug delivers to patients.
I love this line. We should do it for oxygen. Your bill is pretty high because oxygen delivers a lot of value.
Pricing should be based on cost of provision. Because if it is higher in a market economy someone else can enter the market and provide at a lower cost.
I love this line. We should do it for oxygen. Your bill is pretty high because oxygen delivers a lot of value.
Pricing should be based on cost of provision. Because if it is higher in a market economy someone else can enter the market and provide at a lower cost.